Authors: Cinzia Colombo, Paola Mosconi, Walter Villani, Silvio Garattini
DOI: 10.1371/journal.pone.0034974
Abstract Summary
Italian patient advocacy groups show poor transparency about pharmaceutical funding on their websites. Only 29% disclosed drug company sponsors, just 6% revealed funding amounts, and none reported the proportion of income from pharma. While 76% of drug companies listed funded groups, few provided complete details. Better disclosure standards are urgently needed to maintain public trust.
Why Brain? 🧠
Italian patient groups rarely disclose pharmaceutical funding on websites, while drug companies more often list sponsored groups but omit funding amounts, revealing poor transparency needing improvement.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
